Mylan Specialty L.P. Announces 25th Anniversary Celebration of EpiPen® (epinephrine) Auto-Injector

    Mylan Specialty L.P. Announces 25th Anniversary Celebration of EpiPen®
                         (epinephrine) Auto-Injector

Marketer of EpiPen® Auto-Injector, the No. 1 prescribed epinephrine
auto-injector, announces additional efforts to increase anaphylaxis awareness,
preparedness and access to treatment for those affected by life-threatening

PR Newswire

BASKING RIDGE, N.J., April 25, 2013

BASKING RIDGE, N.J., April 25, 2013 /PRNewswire/ --Mylan Specialty L.P., the
fully integrated specialty pharmaceutical business of Mylan Inc. (Nasdaq:
MYL), is celebrating the 25^th anniversary of the U.S. Food and Drug
Administration's (FDA) approval of the EpiPen^® (epinephrine) Auto-Injector.
This innovative epinephrine auto-injector, the first of its kind, was
developed for the emergency treatment of severe allergic reactions
(anaphylaxis). Today, with more than 46 million EpiPen Auto-Injectors
dispensed, it remains the No. 1 prescribed epinephrine auto-injector.

In recognition of this important milestone, Mylan Specialty recently
introduced the 25^th anniversary "$0 Co-Pay Offer." As is consistent with
Mylan's commitment to providing people access to high quality medicine, this
co-pay card is available to both cash-paying and commercially insured
patients. Certain restrictions apply. Additional information about the co-pay
card is available online at, and the coupon is available to
patients through physicians across the country. The "$0 Co-Pay Offer" is valid
for up to three EpiPen 2-Pak^® cartons or EpiPen Jr 2-Pak^® cartons per
prescription, as patients may need to access two EpiPen or EpiPen Jr^®
(epinephrine) Auto-Injectors in multiple locations. Eligible patients can use
the offer with an unlimited number of prescriptions until the coupon offer
expires on December 31, 2013.

"Mylan has a long-standing dedication to increasing access to epinephrine
auto-injectors through innovative access solutions such as the EpiPen4Schools
program, and we're pleased to continue that commitment by introducing our $0
Co-Pay Offer," said Heather Bresch, CEO of Mylan. 

Immediate access to epinephrine, the medication delivered by EpiPen
Auto-Injector, is a critical component of an anaphylaxis action plan. Since
2009, EpiPen Auto-Injectors have delivered an injection of epinephrine using
built-in needle protection, so people never see or are exposed to the needle
before and after use. Those known to be at risk for anaphylaxis should have an
action plan that includes avoiding known allergens, recognizing symptoms,
having access to two epinephrine auto-injectors at all times and seeking
immediate emergency medical care should anaphylaxis occur.

"As part of this important anniversary year we also want to celebrate the
millions of people, from emergency responders and school nurses to caregivers
and patients, who are trained on and prepared with our EpiPen Auto-Injector in
the event anaphylaxis occurs," said Bresch. "We recognize that with the
increase in food allergies, that the risk of anaphylaxis may be on the rise,
and as the leading marketers of epinephrine auto-injectors for 25 years, we
will continue to introduce educational efforts that lead to greater
anaphylaxis awareness and preparedness."

As Mylan Specialty rolls out several new programs this year, the company will
continue to partner with trusted advocacy organizations from across the
country to increase awareness and preparedness of life-threatening allergic
reactions. Advocacy organizations including Allergy & Asthma Network Mothers
of Asthmatics (AANMA), the American Latex Allergy Association (ALAA), Asthma
and Allergy Foundation of America (AAFA), Food Allergy Research & Education
(FARE), Kids With Food Allergies Foundation (KFA) and the National Association
of School Nurses (NASN) continue with outstanding success to unite their
members around this important issue. Mylan Specialty is proud to collaborate
with these allies on both new and existing educational activities focusing on
anaphylaxis awareness and preparedness.

"For 25 years, the EpiPen Auto-Injector has helped people with potentially
life-threatening allergies be better prepared for an anaphylactic reaction,
whether they are going out todinner, heading off for the first day of school
or traveling to a foreign destination," said Bill McLin, President and CEO of
AAFA. "AAFA is proud to partner with Mylan Specialty and to continue our work
with them on many initiatives to increase awareness about life-threatening
allergies and improve access to emergency epinephrine treatment."

Additional plans by Mylan Specialty to honor the 25^th anniversary of EpiPen
Auto-Injector will be announced soon.

For more information on anaphylaxis, life-threatening allergies and EpiPen
Auto-Injector, visit

EpiPen^® (epinephrine) 0.3 mg and EpiPen Jr^® (epinephrine) 0.15 mg
Auto-Injectors are for the emergency treatment of life-threatening allergic
reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers;
and for people who are at increased risk for these reactions. EpiPen and
EpiPen Jr are intended for immediate self administration as emergency
supportive therapy only. Seek immediate emergency medical treatment after use.

Important Safety Information
EpiPen Auto-Injectors contain a single dose of epinephrine, which you inject
HANDS OR FEET. In case of accidental injection, please seek immediate medical
treatment. Epinephrine should be used with caution if you have heart disease
or are taking certain medicines that can cause heart-related (cardiac)

Tell your doctor if you have certain medical conditions such as asthma,
depression, thyroid disease, Parkinson's disease, diabetes, high blood
pressure and heart disease, have any other medical conditions, are pregnant or
plan to become pregnant, or are breastfeeding or plan to breastfeed. Be sure
to also tell your doctor all the medicines you take, especially medicines for
asthma. If you have certain medical conditions, or take certain medicines,
your condition may get worse or you may have longer lasting side effects when
you take the EpiPen or EpiPen Jr Auto Injector.

The most common side effects may include increase in heart rate, stronger or
irregular heartbeat, sweating, nausea and vomiting, difficulty breathing,
paleness, dizziness, weakness or shakiness, headache, apprehension,
nervousness or anxiety. These side effects usually go away quickly, especially
if you rest.

Talk to your healthcare professional to see if EpiPen or EpiPen Jr
Auto-Injector is right for you.

Please click here or visit for the EpiPen Auto-Injector
prescribing information.

Please click here or visit for the EpiPen Auto-Injector patient

You are encouraged to report negative side effects of prescription drugs to
the FDA.

Visit or call 1-800-FDA-1088.

About the "$0 Co-Pay Offer" Card
Mylan Specialty is excited to offer the 25^th anniversary "$0 Co-Pay Offer"
card. The offer is available to both cash-paying and commercially insured
patients, including those with a high deductible. Certain restrictions apply.
The "$0 Co-Pay Offer" (with maximum benefit up to $100 per each EpiPen 2-Pak)
is valid for up to three EpiPen 2-Pak cartons or EpiPen Jr 2-Pak cartons per
prescription. Eligible patients can use the offer an unlimited number of times
until the expiration date, December 31, 2013. The co-pay card is available
through physicians across the country. Patients can contact Mylan Customer
Service at 1-800-796-9526 with any questions, and can obtain additional
information about the co-pay card at In addition to this offer,
EpiPen Auto-Injector continues to have more than 97% Tier 2 Preferred
Commercial Coverage.

About the EpiPen4Schools™ Program
The EpiPen4Schools program offers four free EpiPen or EpiPen Jr
Auto-Injectors, upon qualification, which includes having a valid
prescription, to public and private kindergarten, elementary, middle and high
schools in the U.S. The products are available in the form of two EpiPen 2-Pak
cartons, two EpiPen Jr 2-Pak ^ cartons or one 2-Pak of each kind. EpiPen
Auto-Injectors contain a single dose of epinephrine, which you inject into
your outer thigh. EpiPen and EpiPen Jr are intended for immediate self
administration as emergency supportive therapy only. Seek immediate emergency
medical treatment after use. In addition to the EpiPen4Schools program, Mylan
Specialty offers a discount program through which schools can purchase, upon
qualification, EpiPen 2-Pak (0.3 mg) cartons and EpiPen Jr 2-Pak (0.15 mg)
cartons at a discounted price. There is no requirement for a school to
purchase additional EpiPen Auto-Injectors or any other Mylan Specialty
products. For complete program details, visit

About Anaphylaxis
Anaphylaxis is a life-threatening allergic reaction that has many possible
triggers, occurs quickly, without warning, and must be treated immediately
with epinephrine. Symptoms may include hives or redness of the skin, tightness
in the throat, nausea, dizziness, breathing problems, a decrease in blood
pressure and/or fainting. Anaphylaxis can be caused by triggers such as food,
stinging and biting insects, medicines, latex or even exercise. Epinephrine is
the only first-line treatment for anaphylaxis. According to the food allergy
guidelines developed by the National Institute of Allergy and Infectious
Diseases, if experiencing anaphylaxis, a person should use an epinephrine
auto-injector and seek immediate emergency medical attention. Epinephrine is a
naturally-occurring hormone, also known as adrenaline, and it should be
available at all times to patients at risk. Delays in epinephrine
administration have been associated with negative health consequences, even
possibly death.

About EpiPen^® Auto-Injector
EpiPen^® and EpiPen Jr^® Auto-Injectors are used for the emergency treatment
of life-threatening allergic reactions. Each EpiPen 2-Pak^® and EpiPen Jr
2-Pak^® contains two single auto-injectors, instructions for use and a
training device, with no drug product or needle, to help patients become
familiar with the administration technique. EpiPen Auto-Injector should be
administered immediately at the first sign of an anaphylactic reaction. EpiPen
Auto-Injector is not a substitute for emergency medical treatment. [ ]Patients
should seek emergency medical attention immediately following administration.
EpiPen Auto-Injector has been the No. 1 prescribed epinephrine auto-injector
for 25 years and has three-step easy-to-follow instructions for use. More than
46 million EpiPen Auto-Injectors have been dispensed. For more information
about EpiPen Auto-Injector, please visit

About Mylan Specialty
Mylan Specialty, a subsidiary of Mylan Inc. (NASDAQ: MYL), is a specialty
pharmaceutical company focused on the development, manufacturing and marketing
of prescription drug products for the treatment of respiratory diseases,
life-threatening allergic reactions and psychiatric disorders. For more
information, please visit

About Mylan
Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of approximately 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside.

EpiPen^®, EpiPen Jr^®, EpiPen 2-Pak^®, and EpiPen Jr 2-Pak^® are registered
trademarks of Mylan Inc. licensed exclusively to its wholly-owned subsidiary,
Mylan Specialty L.P.

EpiPen4Schools™ is a trademark of Mylan Specialty L.P.

© 2013 Mylan Specialty L.P. All rights reserved.


SOURCE Mylan Specialty L.P.

Contact: Nina Devlin (Media), 724.514.1968, or Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.